Medical devices, healthcare technology and the business of care
510(k) clearance · K263016

Intra-Operative Positioning System (IOPS) and IOPS Visionary System

Centerline Biomedical · Decision date Oct 1, 2026

MEDTECHLEDGER EXPLANATIONK263016

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 2026-10-01 for K263016, the Intra-Operative Positioning System (IOPS) and IOPS Visionary System, submitted by Centerline Biomedical of Warrensville Heights, Ohio. The application was received 08/28/2026 under regulation 870.1425, device classification name Computer, Diagnostic, Programmable, with primary product code DQK and subsequent codes DQX and DQY. The regulation medical specialty and 510(k) review panel are both Cardiovascular. SESE in a 510(k) pathway denotes clearance for marketing, not PMA approval.

The record describes the submission type as Special, states that it was not reviewed by a third party, is not a combination product, and that no Predetermined Change Control Plan was authorized. The listed summary document was not available in the public information, so the specific device components, any changed items relative to a predicate, and the basis for the equivalence determination remain unknown. The subsequent product codes DQX and DQY are listed without explanation of their relationship to the subject device. No clinical performance, indications for use, or postmarket obligations can be characterized from this record.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Oct 1, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K263016
Regulatory pathway
510(k) premarket notification
Product code
DQK
Decision code
SESE
Decision date
Oct 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Computer, Diagnostic, Programmable.

Product code
DQK
FDA device class
2

FDA decision timeline

  1. K263016 received

    Application receipt date recorded by FDA.

  2. K263016 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code DQK

Product / regulatory recordCompanyPathwayDecision dateSource
Merge Healthcare Incorporated510(k) clearanceNov 5, 2026FDA
Catheter Precision, Inc.510(k) clearanceOct 30, 2026FDA
PulseAI, Ltd.510(k) clearanceOct 27, 2026FDA
Rhythm AI, Ltd.510(k) clearanceOct 23, 2026FDA
Wellysis Corp.510(k) clearanceSep 25, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Centerline Biomedical

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Warrensville Heights, OH

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records